Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
KING OF PRUSSIA, Pa., March 02, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 8, 2017 at 8:00 am EST to review financial results as of and for the year ended December 31, 2016 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 81728820).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 81728820). Following the conclusion of the call, the webcast will be available for replay for 30 days.
Separately, the Company will be webcasting its corporate presentation at the Cowen 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. EST in Boston. This presentation will include discussion of how recently-reported data support the Company’s plans for regulatory approval and subsequent commercialization of OLINVO™ (oliceridine injection) in the U.S.
To join a live audio webcast of the Cowen presentation, please visit the Investor Presentation section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734 for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
